TORONTO, Sept. 6,
2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the
"Company") (TSX: HLS), a pharmaceutical company focusing on central
nervous system ("CNS") and cardiovascular markets, announces that
Craig Millian, Chief Executive
Officer, will present at H.C. Wainwright's 25th Annual Global
Investment Conference, which takes place September 11-13, 2023 at the Lotte New York
Palace Hotel in New York City.
HLS will present on September 12,
2023, at 2:30 p.m. Eastern
Time. The Company's presentation will be webcast at:
https://journey.ct.events/view/381019f3-cd51-43fe-b0aa-b0b0699804b3.
The presentation will be archived for 90 days and will also be
available on the Events page in the Investor section of the
Company's website.
Mr. Millian and Tim Hendrickson,
Chief Financial Officer, will also host one-on-one meetings with
investors at the conference. To request a one-on-one meeting,
please contact your H.C. Wainwright representative. For more
information about the conference, please visit the conference
website
ABOUT HLS THERAPEUTICS
INC.
Formed in 2015, HLS is a pharmaceutical company focused on the
acquisition and commercialization of late-stage development,
commercial stage promoted and established branded pharmaceutical
products in the North American markets. HLS's focus is on products
targeting the central nervous system and cardiovascular therapeutic
areas. HLS's management team is composed of seasoned pharmaceutical
executives with a strong track record of success in these
therapeutic areas and at managing products in each of these
lifecycle stages. For more information visit:
www.hlstherapeutics.com
ABOUT H.C. WAINWRIGHT &
CO.
H.C. Wainwright is a full-service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research and
sales and trading services to institutional investors. According to
Sagient Research Systems, H.C. Wainwright's team is ranked as the
#1 Placement Agent in terms of aggregate CMPO (confidentially
marketed public offering), RD (registered direct offering) and PIPE
(private investment in public equity) executed cumulatively since
1998. For more information visit H.C. Wainwright & Co. at
www.hcwco.com
SOURCE HLS Therapeutics Inc.